GlassScriptPhysician profile
Thomas C Fiest
NPI 1265533772
$3,057.94
in general payments reported to CMS, 2019-2025
26 companies · $843 in 2025
The $843 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $61.25 · 2021: $349 · 2022: $283 · 2023: $531 · 2024: $692 · 2025: $843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927 · Education: $99.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.27 |
| Education | $99.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $653.70 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $612.34 | 2019-2025 | |
| Pfizer INC. | $598.18 | 2019-2025 | |
| Genzyme Corporation | $168.47 | 2023-2025 | |
| Celgene Corporation | $144.63 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $119.53 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $100.90 | 2024-2025 | Resmetirom, Rezdiffra |
| Ferring Pharmaceuticals INC. | $94.08 | 2022-2023 | Cimzia, Rebyota |
| Gilead Sciences, INC. | $84.11 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.63 | 2019-2024 | Entyvio |
| Amgen INC. | $56.68 | 2022-2023 | Amjevita |
| Merck Sharp & Dohme LLC | $46.31 | 2022-2024 | Dificid |
| Qol Medical, LLC | $40.18 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $32.09 | 2023 | Dupixent |
| Daiichi Sankyo INC. | $31.89 | 2023 | Injectafer |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $26.15 | 2020-2021 | |
| Allergan, INC. | $22.03 | 2020 | |
| Capsovision, INC. | $21.41 | 2023 | Capsocam Plus |
| Ironwood Pharmaceuticals, INC | $19.69 | 2024 | |
| Ethicon US, LLC | $17.74 | 2019 | |
| Novo Nordisk INC | $16.93 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $16.60 | 2025 | Iqirvo |
| Braintree Laboratories, INC. | $13.98 | 2025 | Sutab, Suflave |
| Organon LLC | $13.96 | 2023 | Renflexis, Hadlima |
| Intra-Sana Laboratories | $13.58 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.15 | 2024 | Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Fiest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.